Sort
21,281 grants matching “influenza”
Aminoglycosides with reduced ototoxicity
$999,986Dev Priya Arya · Nubad, Llc · R42 · FY2021 · AI
Annual Estimates of Influenza Vaccine Effectiveness: Davidson County, TN
$999,985Marie R Griffin · Vanderbilt University · U18 · FY2010 · IP
Development of peptide nucleic acid antibiotics
$999,985Dev Priya Arya · Nubad, Llc · R42 · FY2021 · AI
Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu
$999,975Elke Lipka · Tsrl, Inc. · R44 · FY2025 · AI
AMERICAN AGRICULTURE USES A JUST-IN-TIME DELIVERY MODEL WHERE AN EGG LAID OR LOIN HARVESTED TODAY MAY BE ON STORE SHELVES TOMORROW. WHEN OUTBREAKS HAPPEN, MOVEMENTS --INCLUDING THOSE FROM UNINFECTED FARMS--MAY BE STOPPED TO PREVENT DISEASE SPREAD. THE COLLATERAL DAMAGE FROM STOPPING AGRICULTURAL PRODUCT MOVEMENTS MAY BE A LARGER THREAT TO ANIMAL WELFARE, THE FOOD SUPPLY, SOCIAL STABILITY, AND RURAL ECONOMIC VIABILITY THAN THE DISEASE ITSELF. THE SECURE FOOD SYSTEMS (SFS) APPROACH IS A WAY TO PREVENT DAMAGE WHILE MAINTAINING FOOD PRODUCTION AND ACCESS TO MARKETS. THE APPROACH INCLUDES ELUCIDATING INFECTION PATHWAYS AND DEVELOPING PRACTICAL BIOSECURITY MEASURES TO MITIGATE THOSE INFECTION RISKS. IN ADDITION, SCIENTIFICALLY-SOUND DISEASE DETECTION STRATEGIES ARE DEVELOPED TO SUPPORT RISK-BASED PERMITTED ANIMAL AND AGRICULTURAL PRODUCT MOVEMENTS FROM UNINFECTED PRODUCTION PREMISES WITHIN OUTBREAK CONTROL AREAS. IN 2015, 2016 AND 2017, THIS APPROACH WAS SUCCESSFULLY USED FOR POULTRY-TO-MARKET MOVEMENTS DURING THE H5 AVIAN INFLUENZA OUTBREAKS BECAUSE PRODUCERS AND REGULATORS WERE ABLE TO FOLLOW THE PROACTIVELY DEVELOPED GUIDANCES IN THE SECURE POULTRY SUPPLY PLAN. ADDITIONALLY, SFS APPROACHES ARE LINKED TO THE PROGRAM PRIORITIES BECAUSE THEY STRATEGICALLY INCREASE BIOSECURITY, PRUDENTLY MANAGE RESOURCES, AND PRODUCE APPLIED AND RELEVANT RESEARCH THROUGH EFFECTIVE COLLABORATIONS AND PUBLIC-PRIVATE PARTNERSHIPS. THEREFORE, WE PROPOSE TO EXPAND THE SFS TO TACKLE OTHER PATHOGENS AND MOVEMENTS WITH NEW APPROACHES FOLLOWING THE PROVEN METHODS ABOVE TO DEVELOP TACTICAL STRATEGIES FOR LIMITING DISEASE OUTBREAK SPREAD IN AGRICULTURE SYSTEMS AND PERFORMING OUTREACH TO EDUCATE AGRICULTURE INDUSTRIES ON HOW TO USE THE SFS PLATFORM TO EFFECTIVELY PREPARE FOR AND RESPOND TO DISEASE EMERGENCIES. ?
$999,968Regents Of The University Of Minnesota · · FY2020 · National Institute of Food and Agriculture
Therapeutic Antibodies for Biofilm Infections
$999,961Lawrence Michael Kauvar · Trellis Bioscience, Inc. · SB1 · FY2019 · AI
Therapeutic Antibodies for Biofilm Infections
$999,953Lawrence Michael Kauvar · Trellis Bioscience, Inc. · SB1 · FY2017 · AI
Modeling the ecology of tissue-resident T cells
$999,932Andrew Yates · Columbia University Health Sciences · U01 · FY2021 · AI
Novel Strategies to Clear Bacteria from the CF Lung
$999,919Saira Ahmad · Eldec Pharmaceuticals, Inc. · R44 · FY2022 · HL
Improved Influenza Vaccine Efficacy Through Infection Mimicry
$999,900Kathryn Kosuda · Vaxess Technologies, Inc. · R44 · FY2021 · AI
A Multiplexed Diagnostic Platform for Bioagent Detection
$999,900University Of Calif-Lawrnc Lvrmr Nat Lab · U01 · FY2004 · AI
PIPP Phase I: Dynamics of Pandemic Spread and Prevention in Indigenous Communities
$999,894Anand Jagota · Lehigh University · · FY2022 · SBE
IHBEM: Enhancing Influenza Forecasting Through an Integrated Platform for User-Generated Temporal Forecasts
$999,886Thomas C McAndrew · Lehigh University · · FY2024 · MPS
Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections
$999,862Elke Lipka · Tsrl, Inc. · R44 · FY2022 · AI
Strain-Independent Therapeutic Antibodies for Influenza
$999,820Lawrence Michael Kauvar · Trellis Bioscience, Inc. · R44 · FY2022 · AI
Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine
$999,762Christopher Locher · Versatope Therapeutics, Inc. · R44 · FY2024 · AI
Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu
$999,746Elke Lipka · Tsrl, Inc. · R44 · FY2024 · AI
System for faster microarray assays and end-to-end workflow automation
$999,735Jay Kenneth Fisher · Redbud Labs, Inc. · R44 · FY2019 · GM
Aminoglycosides with reduced ototoxicity
$999,707Dev Priya Arya · Nubad, Llc · R42 · FY2023 · AI
Aminoglycosides with reduced ototoxicity
$999,707Dev Priya Arya · Nubad, Llc · R42 · FY2024 · AI
Preclinical development of an important, broad-spectrum antibody for pandemic influenza
$999,635Colleen Doyle Cooper · Celdara Medical, Llc · R44 · FY2023 · AI
Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections
$999,604Elke Lipka · Tsrl, Inc. · R44 · FY2023 · AI
Research on the Epidemiology, Vaccine Effectiveness and Treatment of Influenza and Other Respiratory Viruses in Southeast Asia and the Western Pacific
$999,559Benjamin John Cowling · University Of Hong Kong · U01 · FY2016 · IP
Development of peptide nucleic acid antibiotics
$999,557Dev Priya Arya · Nubad, Llc · R42 · FY2023 · AI
Diagnostic Influenza RT-PCR Array
$999,468Darrell P Chandler · Akonni Biosystems, Inc. · R44 · FY2009 · AI